New ECLIPSE study validates the accuracy of Shield.  See the data

Accurate blood-based CRC screening.1

Simply done.

Thank you for your interest in receiving the latest updates on Shield™.
Please provide your information below to sign up.

By clicking the Sign Up button, you agree to receive periodic product-related updates via email from Guardant Health.

1. Kim ST, Raymond VM, Park JO, et al. Combined genomic and epigenomic assessment of cell-free circulating tumor DNA (ctDNA) improves assay sensitivity in early-stage colorectal cancer (CRC). Cancer Res. 2019;79(suppl 13):916. doi:10.1158/1538-7445.AM2019-916